Infliximab Biosimilars Not Linked to Worsened Infection Risk

An analysis of national Canadian data suggest patients receiving either originator or biosimilar infliximab are at a similar risk of the common adverse event.

Related Keywords

Canada , Canadian , Marinag Birck , Linkedin Marinag Birck , , Canadian National Prescription Drug Utilization Information System , National Ambulatory Care Reporting System , International Conference On Pharmacoepidemiology , International Conference , Therapeutic Risk Management , Annual Meeting , Research Institute , Mcgill University Health Centre , Hospital Discharge Abstract Database , National Ambulatory Care Reporting , Biosimilar , Infliximab , Biologic , Infection , Risk , Safety , Study , Outcomes , Remicade ,